secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001213900-25-023789
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q2 net loss $4.6M vs prior year net income; merger with Cyclo pending
--------------------------------------------------------------------------------

- Net loss of $4.6M ($0.19/sh) for Q2 ended Jan 31, 2025 vs net income of $6.0M ($0.25/sh) a year ago.
- Cash and equivalents at $48.3M as of January 31, 2025.
- Merger with Cyclo Therapeutics (CYTH) expected to close in Q3 fiscal 2025 pending shareholder approvals.
- Topline data from interim analysis (48 weeks) of Phase 3 Trappsol Cyclo for NPC1 expected mid-2025.
- R&D expenses rose to $0.9M from $0.6M due to consolidation of Cornerstone and Day Three.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/0001213900-25-023789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/ea0234181-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-023789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer